BBI608-503-103HCC: A phase Ib/II clinical study of napabucasin (BBI608) in combination with sorafenib or amcasertib (BBI503) in combination with sorafenib (Sor) in adult patients with hepatocellular carcinoma (HCC).

被引：6
|
作者：
El-Rayes, Bassel F.
Richards, Donald A.
Cohn, Allen Lee
Richey, Stephen Lane
Feinstein, Trevor
Kundranda, Madappa N.
El-Khoueiry, Anthony B.
Melear, Jason M.
Braiteh, Fadi S.
Hitron, Matthew
Ortuzar, Waldo Feliu
Khan, Waheed
Xu, Bo
Li, Wei
Li, Youzhi
Li, C. J.
机构：
[1] Winship Canc Inst, Atlanta, GA USA
[2] Texas Oncol, Tyler, TX USA
[3] Rocky Mt Canc Ctr, Denver, CO USA
[4] US Oncol Network, McKesson Specialty Hlth, Texas Oncol, Ft Worth, TX USA
[5] Piedmont Canc Inst, Fayetteville, GA USA
[6] Banner MD Anderson Canc Ctr, Gilbert, AZ USA
[7] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[8] Texas Oncol, Round Rock, TX USA
[9] US Oncol Network, McKesson Specialty Hlth, The Woodlands, TX USA
[10] Boston Biomed Inc, Cambridge, MA USA
[11] Eli Lilly & Co, Indianapolis, IN 46285 USA
[12] Boston Biomed Inc, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.4077
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4077
引用
收藏
页数：5
相关论文
共 44 条
  • [31] A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma (HCC)
    Harding, James J.
    Abou-Alfa, Ghassan K.
    Shi, Yuankai
    Whang-Peng, Jacqueline
    Yuen, Man Fung
    Saif, Wasif M.
    Tian, Aiping
    Gu, Shanzhi
    Lam, Wing
    Liu, Shwu-Huey
    Cheng, Yung-Chi
    Chu, Edward
    Yen, Yun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [32] Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
    Lee, Francis A. S.
    Zee, Benny Chung-Ying
    Cheung, Foon Yiu
    Kwong, Philip
    Chiang, Chi Leung
    Leung, Kwong Chuen
    Siu, Steven W. K.
    Lee, Conrad
    Lai, Maria
    Kwok, Chloe
    Chong, Marc
    Jolivet, Jacques
    Tung, Steward
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (06): : 609 - 613
  • [33] CLINICAL UPDATE ON THE PHASE I/II TRIAL OF HDAC INHIBITOR RESMINOSTAT IN PATIENTS WITH SORAFENIB-RESISTANT HEPATOCELLULAR CARCINOMA (HCC) - THE SHELTER STUDY
    Bitzer, Michael
    Horger, Markus
    Ganten, Tom
    Ebert, Matthias P.
    Siveke, Jens T.
    Woerns, Marcus A.
    Dollinger, Matthias M.
    Gerken, Guido
    Scheulen, Max E.
    Mais, Anna
    Jankowsky, Ruediger
    Hauns, Bernhard
    Hentsch, Bernd
    Lauer, Ulrich M.
    ANNALS OF ONCOLOGY, 2011, 22 : v76 - v76
  • [34] Clinical update on the SHELTER study: A phase I/II trial of the HDAC inhibitor resminostat in patients with sorafenib-reistant hepatocellular carcinoma (HCC).
    Bitzer, M.
    Horger, M.
    Ganten, T.
    Ebert, M. P.
    Woerns, M. A.
    Dollinger, M. M.
    Mais, A.
    Hauns, B.
    Hentsch, B.
    Lauer, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [35] Investigation of the HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC): Clinical data from the phase I/II SHELTER study
    Bitzer, Michael
    Horger, Marius
    Ganten, Tom M.
    Siveke, Jens T.
    Woerns, Marcus A.
    Dollinger, Matthias M.
    Gerken, Guido
    Scheulen, Max E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [36] Clinical update on a phase I/II trial of HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC): The SHELTER study.
    Bitzer, M.
    Horger, M.
    Ganten, T. M.
    Ebert, M. P.
    Siveke, J. T.
    Woerns, M. A.
    Dollinger, M. M.
    Gerken, G.
    Scheulen, M. E.
    Mais, A.
    Jankowsky, R.
    Hauns, B.
    Hentsch, B.
    Lauer, U. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [37] Phase I portion of the phase I-II study of the X-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Lee, A. S.
    Zee, B. C.
    Lai, M.
    Jolivet, J.
    Wong, C. S.
    Chiang, C. L.
    Tong, M.
    Tung, S. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Phase 1b study of R05137382/GC33 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) (NCT00976170).
    Abou-Alfa, Ghassan K.
    Yen, Chia-Jui
    Carrasquillo, Jorge A.
    Hsu, Chih-Hung
    Gansukh, Bolorsukh
    Ma, Jennifer
    Hollywood, Ellen
    Wan, Peter J.
    Shao, Yu Yun
    Lin, Zhong-Zhe
    Frenette, Catherine
    O'Neil, Bert H.
    Schwartz, Lawrence H.
    Ohtomo, Toshihiko
    Tanaka, Takayoshi
    Chen, Ya-Chi
    Ukrainskyj, Stacey
    Saltz, Leonard
    Lee, Reuymin
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] A randomized phase II open label multi-institution study of the combination of bevacizumab (B) and erlotinib (E) compared to sorafenib (S) in the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC).
    Thomas, Melanie B.
    Garrett-Mayer, Elizabeth
    Anis, Munazza
    Anderton, Kate Robertson
    Bentz, Tricia A.
    Adelman, Andie Ray
    Brisendine, Alan
    Duddalwar, Vinay
    Weiss, Geoffrey R.
    Siegel, Abby B.
    Bendell, Johanna C.
    Baron, Ari David
    El-Khoueiry, Anthony B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [40] A phase II (PhII) trial of sorafenib (S) in combination with 5-fluorouracil (5FU) continuous infusion (c.i.) in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary data
    Petrini, I.
    Lencioni, M.
    Ricasoli, M.
    Iannopollo, M.
    Orlandini, C.
    Oliveri, F.
    Filipponi, F.
    Bartolozzi, C.
    Del Tacca, M.
    Ricci, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345